Improvements in the long-term survival of cancer patients have led to growing awareness of the clinical importance of cancer therapeutics-related cardiac dysfunction (CTRCD), which can have a considerable effect on the prognosis and quality of life of cancer patients and survivors. Under such circumstances, onco-cardiology/cardio-oncology has emerged as a new discipline, with the aim of best managing cardiovascular complications, including CTRCD. Despite the recent accumulation of epidemiological and clinical information regarding CTRCD, the molecular mechanisms underlying the pathogenesis of CTRCD by individual drugs remain to be determined. To achieve the goal of preventing cardiovascular complications in cancer patients and survivors, it is important to elucidate the pathogenic mechanisms and to establish diagnostic strategies with risk prediction and mechanism- and evidence-based therapies against CTRCD.

癌症患者长期生存率的改善导致人们越来越意识到癌症治疗相关心功能障碍 (CTRCD) 的临床重要性，这可能对癌症患者和幸存者的预后和生活质量产生相当大的影响。在这种情况下，肿瘤心脏病学/心脏肿瘤学已成为一门新学科，旨在最好地管理心血管并发症，包括 CTRCD。尽管最近积累了有关 CTRCD 的流行病学和临床信息，但单个药物导致 CTRCD 发病机制的分子机制仍有待确定。为实现预防癌症患者和幸存者心血管并发症的目标，